Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03248037 · ClinicalTrials.gov registry record · Phase 3
Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation
A Phase 3 study, sponsored by Cornea Research Foundation of America.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT03248037: Completed Phase 3 study, sponsored by Cornea Research Foundation of America.
NCT03248037 is a Phase 3 study that has completed, run by Cornea Research Foundation of America. The registered enrollment target is 120 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03248037, a Phase 3 study, has completed, sponsored by Cornea Research Foundation of America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
Cornea transplant recipients who are using topical corticosteroids long-term to prevent transplant rejection will be randomized to use netarsudil or placebo.
Primary Outcome
Intraocular pressure measurement exceeding 24 mm Hg or more than 10 mm Hg greater than the pre-randomization reading.
Interventions
- DRUG Placebo
- DRUG Netarsudil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-09-05 |
| Est. Completion | 2019-07-09 |
| Phase | Phase 3 |
What the finished NCT03248037 record still lists
NCT03248037 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03248037 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03248037 about?
NCT03248037 is a clinical study titled "Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation". Cornea transplant recipients who are using topical corticosteroids long-term to prevent transplant rejection will be randomized to use netarsudil or placebo.
What is the current status of trial NCT03248037?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2017-09-05. Estimated completion is 2019-07-09.
What interventions are being tested in trial NCT03248037?
The interventions under investigation include: Placebo (DRUG), Netarsudil (DRUG).
Who is sponsoring clinical trial NCT03248037?
This trial is sponsored by Cornea Research Foundation of America, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03248037's enrollment target sits among peer trials
120 1619th of 2000 higher than 361 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI